Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated infliximab infusions in inflammatory bowel disease
2021-000570-28Phase 4Terminated
- Sponsor
- Tampere University Hospital
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of infliximab in inflammatory bowel disease (IBD) (2 arms), sponsored by Tampere University Hospital. Primary endpoints: Infusion reactions with accelerated vs standard infliximab infusions and Effect of premedication on infusion reactions. Started Apr 2021; status: terminated.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2021-000570-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000570-28.